What is BPC-157? Research Based Benefits, Health Canada's Position, the 2026 Recall, and the Evidence

Is BPC-157 legal in Canada? The short answer is that it is not an authorized drug, Health Canada says so by name, and the regulator's position hardened in 2026. Health Canada's April 2026 public advisory lists BPC-157 as unauthorized injectable peptides, a Type I recall in May 2026 covered BPC-157 powder sold to pharmacies as an unauthorized active pharmaceutical ingredient, and in June 2026 a Quebec court granted Health Canada a permanent injunction against a company selling injectable peptides. Almost no Canadian page selling the compound mentions either, and most still describe its human evidence as though it were settled. It is not: the published record is animal and cell work.

This guide covers what BPC-157 is as a molecule, exactly what Health Canada has said and done about it, how to check a Drug Identification Number yourself, what happens to a shipment at the border, where it stands in Canadian sport, what the published research measured, and how to verify a lot of a 15-residue peptide. It is written for laboratory and in-vitro research procurement. It reports what published studies recorded in cell and animal models because that is the public evidence base, and it contains no dosing, administration or human-use guidance, and none should be inferred.

What BPC-157 Is

BPC-157 is a synthetic peptide corresponding to a partial sequence of a protein found in gastric juice. It is 15 amino acids long, which is why the literature calls it a pentadecapeptide.

Those values agree with PubChem CID 9941957. Four of the fifteen residues are proline, and three of those sit consecutively at positions 3 to 5. A proline-rich stretch like that restricts the backbone's conformational freedom, and it matters again when it comes to verifying a lot, because a missing proline is one of the easiest synthesis errors to make.

What "stable gastric pentadecapeptide" does and does not claim

The compound appears throughout the literature as "stable gastric pentadecapeptide BPC 157". The phrase is the originating group's own naming convention, repeated into hundreds of later titles. Read quickly, it sounds like a measured stability result. It is not one.

The most direct evidence is a 2026 review in Pharmaceutics whose entire subject is the compound's biopharmaceutical challenges, formulation strategies and translational development barriers. A compound with settled stability does not need that paper written about it. So the honest reading is narrower than the name: the sequence was selected from a gastric-juice protein and is described as stable in that acidic context by the group that named it. It is not a shelf-life figure, it is not a serum half-life, and it is not a reason to skip the storage conditions on the vial.

Is BPC-157 Legal in Canada?

What Health Canada has said

On 9 April 2026 Health Canada issued public advisory RA-81874, "Think twice before injecting peptides bought online: unauthorized products can seriously harm you." It lists thirteen examples of unauthorized injectable peptide drugs it has seized: BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, ipamorelin, KPV, Melanotan I and II, MOTS-C, SS-31, TB-500 and a GLP-3 RT class compound.

Health Canada then published a dedicated set of pages on peptides, most recently updated on 23 October 2026. Its overview states that the department "has identified a growing number of unauthorized health products containing peptides being promoted for human use and sold in Canada," and names BPC-157 in the list of ingredients those products may contain. It lists "injury recovery" and "athletic performance" among the purposes for which unauthorized synthetic peptides are promoted online.

The regulations page is more specific, and three of its statements decide most questions a Canadian buyer asks:

• "Injectable peptides are always classified as drugs." They are regulated under the Food and Drug Regulations.
• Authorized peptide products carry "an 8-digit drug identification number (DIN) or an 8-digit natural product number (NPN)." Unauthorized ones have neither and "haven't been assessed by Health Canada for safety, efficacy and quality."
• Compounding "must not be used as a means to circumvent the federal drug review and approval process." A compounded product is meant to be prepared for a specific patient's medical need when no authorized product is available, and may not be advertised to the public.

The enforcement tools it lists are recalls, product seizures, requests to stop sales, court-issued entry warrants, permanent injunctions and ministerial orders to stop advertising and sale. The injunction is not theoretical: on 29 July 2026 Health Canada announced that the Quebec Superior Court had granted, on 11 June 2026, a permanent injunction preventing Canlab Research from illegally selling injectable peptides in Canada. The general legal framework, including why a research-use label is not a licence for human use, is set out in are peptides legal in Canada.

The May 2026 recall

Recall RA-82047, posted 7 May 2026 with a recall date of 5 May 2026, is a Type I national recall naming Xenex Laboratories Inc. of Coquitlam, British Columbia. It covers five lots of BPC-157 powder and five lots of GHK-Cu powder in 5 g and 50 g presentations, and the depth of recall is compounding and community pharmacies.

Two details are easy to misread. The stated issue is that the products were unauthorized active pharmaceutical ingredients, which is a market-authorization finding rather than a contamination or potency result, and the recall page describes no specific health risk. And the channel was pharmacies, which is exactly the route the regulations page says compounding may not be used to open. Read together with the peptide guidance, the recall makes Health Canada's position plain: BPC-157 is unauthorized in Canada, and supplying it into the human-use channel is enforced against.

How to check a DIN yourself

Any claim that a peptide is "approved in Canada" can be checked in a minute, and checking it is worth more than any vendor's word.

1. Open Health Canada's Drug Product Database (DPD) search.
2. Search by active ingredient, not by brand name. Use the ingredient's common name and any obvious spelling variant ("BPC-157", "BPC 157").
3. A real authorization returns a product with an 8-digit DIN, a company name and a status such as "Marketed". No result means no authorized drug product with that ingredient under that name.
4. For a natural health product claim, the equivalent register is the Licensed Natural Health Products Database, which lists 8-digit NPNs.

One caution from doing this routinely: absence under one spelling is not proof of absence under every spelling, so search the obvious variants before concluding. For BPC-157, every variant returns nothing.

BPC-157 in Canadian sport

BPC-157 is not named individually on the WADA Prohibited List, but it falls under section S0, which prohibits at all times any pharmacological substance not approved by a government health authority for human therapeutic use. Sport Integrity Canada (formerly the Canadian Centre for Ethics in Sport) has applied that rule. In February 2025 it announced a sanction in which a powerlifting athlete "admitted to the use of BPC-157, a prohibited non-approved substance," and in April 2025 it announced a four-year sanction for a U SPORTS volleyball athlete who used BPC-157 and TB-500 between August and September 2024.

What the Published Research Measured

The BPC-157 literature is large, old and almost entirely preclinical. A reader comparing suppliers will see the volume of citations quoted as though it were evidence of efficacy in people. It is not.

The pattern is consistent. The primary work is in animals, the reviews are numerous, and the recent critical reviews are explicitly about how far the preclinical evidence can be taken. No published human efficacy trial establishes a BPC-157 finding, and the compound holds no marketing authorization in any jurisdiction. Health Canada's own peptide guidance makes the same point from the regulator's side: none of the unauthorized products it lists has been assessed for safety, efficacy or quality.

How to Verify a BPC-157 Lot

At 15 residues BPC-157 sits in a useful middle ground. It is long enough that synthesis can go wrong in ways a chromatogram will show, and short enough that a mass spectrometric identity check is unambiguous.

A purity figure is a ratio and says nothing about how much peptide is in the vial. Net peptide content, reported by nitrogen or by amino acid analysis, tells you what fraction of the powder is the peptide rather than counterion, residual solvent and water. A vial can report 99% chromatographic purity and hold substantially less peptide than the label states, because the two numbers answer different questions. Ask for both, and see chain length and counterion for why the counterion accounts for so much of the gap.

Mass spectrometry answers the identity question. The monoisotopic mass is 1418.7042 Da. Dropping one proline from the Pro-Pro-Pro stretch removes 97.05 Da, a deletion a chromatogram may not resolve cleanly but a mass spectrum will show as a second peak at the wrong mass. The methods are set out in what actually proves a peptide sequence, and the Canadian-specific checklist is in how to verify a peptide in Canada.

BPC-157 Alone and Inside Multi-Component Vials

BPC-157 is stocked on its own in 5 mg and 10 mg vials, with a compound hub at BPC-157. It also appears in multi-component vials, including a two-compound 10 mg vial with TB-500 and an 80 mg four-compound vial that adds GHK-Cu, TB-500 and KPV, whose own evidence is set out in what is KPV peptide.

A composition certificate for a multi-component vial measures each compound separately, as covered in the analytical tradeoffs of a blend. It reports a purity and a net peptide content per component, and it states no single purity for the vial, because the vial is not one substance. That matters more for BPC-157 than for most compounds, because it is the ingredient most often used to name a blend: a vial advertised on the strength of BPC-157 may hold a modest fraction of its total mass as BPC-157, and the per-component masses are on the certificate rather than the label.

Frequently Asked Questions

What is BPC-157?

BPC-157 is a synthetic 15-residue peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, corresponding to a partial sequence of a protein found in gastric juice. Its CAS number is 137525-51-0 and its average mass is 1419.5 g/mol.

Is BPC-157 legal in Canada?

BPC-157 is not an authorized drug in Canada. It has no DIN, no NPN and no Notice of Compliance, and Health Canada names it among the unauthorized peptides being promoted for human use. Selling or promoting an unauthorized health product is illegal, and injectable peptides are always classified as drugs. It is not a controlled substance, and it is supplied as a research material for laboratory use only.

Is BPC-157 approved by Health Canada?

No. An active-ingredient search of the Drug Product Database returns no product containing it, and Health Canada's April 2026 advisory and October 2026 peptide guidance both list it as an unauthorized ingredient.

What did the Health Canada recall say?

Recall RA-82047 is a Type I national recall dated 5 May 2026 naming Xenex Laboratories Inc. of Coquitlam, British Columbia, covering five lots each of BPC-157 and GHK-Cu powder supplied to compounding and community pharmacies. The stated issue is that the products were unauthorized active pharmaceutical ingredients. The recall page describes no specific health risk.

Can you get peptide therapy with BPC-157 in Canada?

Not lawfully as an authorized treatment, because no authorized product exists. Health Canada's guidance says compounding must not be used to get around the drug review process and that compounded products may not be advertised to the public.

Can I order BPC-157 into Canada from another country?

Health Canada states that imported shipments of health products that do not meet Canadian requirements may be refused entry, detained or seized at the border. Ordering from abroad adds that step without changing the product's status.

Is BPC-157 banned in sport?

Yes. It falls under WADA's S0 category of non-approved substances, prohibited at all times, and Sport Integrity Canada sanctioned Canadian athletes for its use in 2025.

Has BPC-157 been tested in humans?

No published human efficacy trial establishes a BPC-157 finding. The literature is rodent and cell-culture work, and recent reviews in orthopaedics and molecular science describe the preclinical evidence as preliminary and the formulation questions as unresolved.

Why does net peptide content matter for BPC-157?

Chromatographic purity is a ratio of peak areas and says nothing about how much peptide the vial holds. Net peptide content answers that second question, and the two can disagree widely.

Is the BPC-157 in a blend the same as in a single-compound vial?

The compound is the same, but the quantity is not the headline figure on a multi-component vial, and a blend certificate reports each compound separately rather than one purity for the vial.

Sources

• Health Canada. Public advisory RA-81874, "Think twice before injecting peptides bought online: unauthorized products can seriously harm you." 9 April 2026.
• Health Canada. "Peptides: Overview" and "Peptides: Regulations and enforcement." Canada.ca, page details 23 October 2026.
• Health Canada. "Health Canada obtains permanent injunction preventing Canlab Research's illegal sale of injectable peptides in Canada." News release, 29 July 2026.
• Health Canada, Recall and safety alert RA-82047, "GHK-Cu & BPC-157 powder: Unauthorized active pharmaceutical ingredients", recall date 5 May 2026, published 7 May 2026. Type I, national, depth of recall compounding and community pharmacies.
• Health Canada Drug Product Database, active-ingredient search for BPC-157 and BPC 157: no result returned, checked 6 November 2026.
• Sport Integrity Canada (formerly CCES). Sanction announcements, 24 February 2025 (powerlifting) and 7 April 2025 (U SPORTS volleyball, BPC-157 and TB-500).
• World Anti-Doping Agency. Prohibited List, section S0, Non-Approved Substances.
• PubChem Compound Summary, CID 9941957 (BPC-157). National Library of Medicine.
• Sikiric P et al. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell and Tissue Research. 2019. PMID 30915550.
• "Stable Gastric Pentadecapeptide BPC 157 and Wound Healing." Frontiers in Pharmacology. 2021. PMID 34267654.
• "Pentadecapeptide BPC 157 and the central nervous system." Neural Regeneration Research. 2022. PMID 34380875.
• "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS Journal. 2025. PMID 40756949.
• "BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers." Pharmaceutics. 2026. PMID 42198317.
• "BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence." International Journal of Molecular Sciences. 2026. PMID 42794771.